Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.51 |
| ▸ | PTGES | O14684 | 4/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.51 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932747 | 1.00 | PPARG (0.51) | PPARGPTGESALOX5PPARACA2 | |
| SCHEMBL15709565 | 0.86 | PPARG (0.48) | PPARGPPARAPPARDLMNASMN1; SMN2 | |
| SCHEMBL15709546 | 0.86 | PPARG (0.48) | PPARGPPARAPPARDLMNASMN1; SMN2 | |
| SCHEMBL1930862 | 0.86 | PPARG (0.48) | PPARGPPARAPPARDLMNASMN1; SMN2 | |
| SCHEMBL1903254 | 0.81 | PPARG (0.48) | PPARGPTGESALOX5PPARACA2 | |
| SCHEMBL9658104 | 0.80 | FOLH1 (0.51) | PPARGPTGESALOX5PPARACA2 | |
| SCHEMBL12076568 | 0.78 | ALDH1A1 (0.40) | CA2MAPK1LMNASMN1; SMN2 | |
| SCHEMBL11840819 | 0.78 | PPARG (0.56) | PPARGPTGESALOX5PPARAFOLH1 | |
| SCHEMBL15709525 | 0.77 | KDM4E (0.49) | PPARACA2MAPK1PPARDLMNA | |
| SCHEMBL1905898 | 0.77 | KDM4E (0.49) | PPARACA2MAPK1PPARDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | FABP3, PC, PAH | PPARG 15/4885PTGES 439/4885ALOX5 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.